Vertex Pharmaceuticals Incorporated  

(Public, NASDAQ:VRTX)   Watch this stock  
Find more results for vrtx
+3.52 (4.42%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 79.50 - 83.81
52 week 78.51 - 143.45
Open 81.94
Vol / Avg. 2.77M/3.18M
Mkt cap 19.95B
P/E     -
Div/yield     -
EPS -2.32
Shares 245.65M
Beta 0.72
Inst. own 97%
Apr 27, 2016
Q1 2016 Vertex Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 8, 2016
Vertex Pharmaceuticals Inc at Cowen Health Care Conference - 10:40AM EST - Add to calendar
Feb 11, 2016
Vertex Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference
Jan 27, 2016
Q4 2015 Vertex Pharmaceuticals Inc Earnings Call
Jan 27, 2016
Q4 2015 Vertex Pharmaceuticals Inc Earnings Release
Jan 11, 2016
Vertex Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 1, 2015
Vertex Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -18.29% -57.15%
Operating margin -13.28% -45.40%
EBITD margin - -45.18%
Return on average assets -12.44% -24.42%
Return on average equity -30.06% -51.49%
Employees 1,830 -
CDP Score - -


50 Northern Ave
BOSTON, MA 02210-1862
United States - Map
+1-617-3416393 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Company’s product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Company’s product KALYDECO is available in the market.

Officers and directors

Jeffrey M. Leiden M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Ian F. Smith CPA Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
David Altshuler M.D., Ph.D. Executive Vice President - Global Research, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Stuart A. Arbuckle Executive Vice President, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Jeffrey A. Chodakewitz M.D. Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Amit K. Sachdev J.D. Executive Vice President - Global Government Strategy, Market Access and Value
Age: 47
Bio & Compensation  - Reuters
Paul M. Silva Senior Vice President, Corporate Controller
Age: 48
Bio & Compensation  - Reuters
Bruce I. Sachs Co-Lead Independent Director
Age: 55
Bio & Compensation  - Reuters
Elaine S. Ullian Co-Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Joshua S. Boger Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters